Has Mounjaro Been Approved by the FDA for Weight Loss?

Last reviewed: July 16, 2026

Last updated: July 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Mounjaro (tirzepatide) is an FDA-approved medication for managing type 2 diabetes, having received clearance in July 2022. While Mounjaro itself has not received FDA approval for weight loss as a standalone indication, tirzepatide has demonstrated substantial weight reduction in clinical studies, leading many healthcare providers to prescribe it off-label for weight management.

FDA Approval Status of Mounjaro for Diabetes

The FDA approved Mounjaro on July 21, 2022, for use in adults with type 2 diabetes. This approval was based on clinical trials demonstrating that tirzepatide improved glycemic control better than competing GLP-1 medications. Mounjaro is classified as a dual GLP-1 and GIP receptor agonist, meaning it activates two separate hormone pathways that regulate blood sugar and appetite.

Mounjaro's diabetes indication focuses on reducing hemoglobin A1C levels and fasting blood glucose in patients with inadequate metabolic control. The approval process included multiple phase 3 trials involving thousands of patients across different diabetes severity levels. Since its approval, Mounjaro has become one of the most widely prescribed newer diabetes treatments in the United States.

Weight Loss Clinical Trial Data for Tirzepatide

Although Mounjaro itself is not FDA-approved for weight loss, separate tirzepatide trials have shown striking weight reduction results. In the SURMOUNT series of clinical trials, patients receiving tirzepatide injections lost between 15% and 22% of their body weight over 72 weeks, depending on the dose. These weight losses occurred in people with obesity or overweight status who also had weight-related health conditions.

The dual mechanism of tirzepatide—targeting both GLP-1 and GIP receptors—appears to produce greater weight reduction than single-pathway GLP-1 medications like semaglutide. Patients in tirzepatide trials experienced reduced appetite, increased feelings of fullness, and improved metabolic rate. Side effects were generally mild to moderate, with nausea being the most commonly reported issue, typically decreasing after the first few weeks of treatment.

Off-Label Prescribing and Weight Management Use

Physicians can prescribe FDA-approved medications off-label for conditions other than those listed in the drug's approved indications. Many doctors now recommend tirzepatide off-label for weight management in patients with obesity, even though this use is not part of Mounjaro's official FDA approval. Off-label prescribing is legal and common in medical practice when healthcare providers believe a medication may benefit their patients.

PlexusDx offers compounded tirzepatide injections at $289/mo month-to-month, or from $249/mo on the 6-month plan, providing access to this dual-pathway GLP-1 medication without waiting for a separate weight loss indication. Unlike brand-name Mounjaro, which requires insurance coverage or out-of-pocket payment at pharmacy prices, PlexusDx compounded tirzepatide is prepared by licensed 503A compounding pharmacies and serves all 50 states without insurance requirements.

Personalized Tirzepatide Treatment at PlexusDx

The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

PlexusDx also offers GLP-Squared Injection, a dual-compound formulation combining semaglutide and tirzepatide in a single injection, at $289/mo month-to-month, or from $249/mo on the 6-month plan. Your dose may need to go up as your body adapts and you progress through treatment. Your price won't—PlexusDx maintains flat monthly pricing across all commitment tiers, with no membership fees and HSA/FSA eligibility for added affordability.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I use Mounjaro for weight loss if my doctor prescribes it off-label?

Yes, physicians can legally prescribe Mounjaro off-label for weight management. However, your insurance may not cover off-label uses. PlexusDx offers compounded tirzepatide injections at $289/mo month-to-month, or from $249/mo on the 6-month plan with no insurance required, serving all 50 states with transparent, flat monthly pricing.

How much weight do people typically lose on tirzepatide?

In the SURMOUNT clinical trials, patients lost 15% to 22% of their body weight over 72 weeks, depending on the dose they received. Weight loss was accompanied by reduced appetite and improved metabolic function. Individual results vary based on diet, exercise, genetics, and other health factors.

What is the difference between Mounjaro and PlexusDx compounded tirzepatide?

Mounjaro is the brand-name version of tirzepatide approved by the FDA for diabetes. PlexusDx compounded tirzepatide contains the same active ingredient but is prepared by licensed 503A compounding pharmacies, costs less, requires no insurance, and is available nationwide. Pricing is $289/mo month-to-month, or from $249/mo on the 6-month plan with flat rates across all dosing tiers.

Are there any serious side effects with tirzepatide?

Tirzepatide is generally well-tolerated, with nausea being the most common side effect, especially in the first few weeks. Other possible effects include vomiting, constipation, and diarrhea. Serious adverse events are rare but can include pancreatitis and thyroid concerns. Always consult your healthcare provider about risks specific to your medical history.

How does the PlexusDx Precision Peptide Genetic Test help with tirzepatide treatment?

The $99 test analyzes 14 genetic pathways and 150+ insights related to peptide therapy response, including variants in GLP1R, GIPR, FTO, and MC4R genes. These results help PlexusDx personalize your tirzepatide dose and treatment plan for better weight loss outcomes and side effect management.

Related Reading

• Mounjaro For Weight Loss 2
• Weight Loss Mounjaro
• Mounjaro Weight Loss By Week
• Weight Loss Injections Mounjaro

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.